<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Mutation of the KRAS (v-Kiras2 Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homologue) gene plays an important role in colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This study examined associations between KRAS gene mutations and clinicopathological and survival data in Chinese patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients were recruited for the detection of KRAS gene mutations using polymerase chain reaction and DNA sequencing </plain></SENT>
<SENT sid="3" pm="."><plain>Data on clinicopathological features and survival times were collected </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The study included 78 CRC patients </plain></SENT>
<SENT sid="5" pm="."><plain>The overall mutation frequency of the KRAS gene at codons 12 and 13 was 33.3% (26/78) </plain></SENT>
<SENT sid="6" pm="."><plain>KRAS gene mutations were significantly associated with poor <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> differentiation and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with the <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS gene had significantly higher median survival times than patients with KRAS gene mutations (35.05 months versus 25.72 months) </plain></SENT>
<SENT sid="8" pm="."><plain>Those with KRAS gene mutations at codons 12 or 13 did not have significantly different median survival times (25.69 months versus 20.67 months, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These findings suggest that a high frequency of KRAS gene mutations exists in Chinese patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and that such mutations are associated with poor survival, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> differentiation and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>